ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona

Memorial Sloan Kettering Cancer Center at ESMO 2026

Oct 23–27, 2026 Madrid, Spain ~37k attendees Website

Memorial Sloan Kettering Cancer Center takes part in 56 sessions at ESMO 2026 in Madrid. Its program spans treatment across cancer types, with a focus on precision oncology and immunotherapy. Topics include using circulating tumor DNA to track remission and resistance, and AI-based integration of real-world data to predict outcomes.

OrganizationESMO 2026 Attendance
Cancer centre & hospital
Cancer treatment and research centre in New York City, New York.
Poster
Fri Oct 23
13:00–15:00
Poster
Fri Oct 23
13:00–15:00
Talk
Fri Oct 23
13:30–13:45
Chair
Fri Oct 23
13:30–15:00
Proffered paper 1: Breast cancer, early and advanced stage
with Gustave Roussy
Breast cancer
Abstract
Fri Oct 23
13:35–13:40
1210RO - Safety and efficacy of ixotatug vedotin (TORL-1-23), a claudin 6-targeted ADC, as monotherapy in germ cell tumors (GCT)
Rapid oral: Genitourinary tumours, prostate, penile and testis
Genitourinary cancersGastrointestinal cancers
Poster
Fri Oct 23
15:15–16:00
A chromosomal instability signature identifies patients with BRCA wild-type cancers who benefit from PARP inhibitors across four HRD-associated cancer types
Friday Poster Display session 3
Gastrointestinal cancersGynaecological cancersBreast cancerBiomarkers & precision oncology
Poster
Fri Oct 23
15:15–16:00
Cell free DNA concordance with tissue sequencing and actionability across clinical states of prostate cancer
Friday Poster Display session 5
Genitourinary cancersBiomarkers & precision oncology
Poster
Fri Oct 23
15:15–16:00
Circulating tumor DNA as a marker of durable remission after non-operative management of mismatch repair deficient rectal cancer
Friday Poster Display session 3
Gastrointestinal cancersBiomarkers & precision oncology
Poster
Fri Oct 23
15:15–16:00
DLL3 PET identifies neuroendocrine differentiation and tumor heterogeneity in advanced prostate cancer
Friday Poster Display session 5
Genitourinary cancers
Poster
Fri Oct 23
15:15–16:00
Poster
Fri Oct 23
15:15–16:00
Genomic characterization and prognostic impact of the TP53-Y220C mutation across solid tumors in real-world data
Friday Poster Display session 3
Sarcoma, CNS, head & neck and rare cancersBiomarkers & precision oncology
Poster
Fri Oct 23
15:15–16:00
Talk
Fri Oct 23
15:15–15:35
RNA vaccines for cancer: Principles to practice
What oncologists should know about mRNA vaccines
Poster
Fri Oct 23
15:15–16:00
Targeting DNA damage repair via exportin-1 inhibition to delay resistance to targeted therapy in RET-fusion lung cancer
Friday Poster Display session 3
Lung & thoracic cancersSarcoma, CNS, head & neck and rare cancers
Talk
Fri Oct 23
16:15–17:15
Learning from setbacks: Redefining success in oncology
YO Vesalius Talk · with Oncology Institute of Southern Switzerland (IOSI), Institut Strauss
Talk
Fri Oct 23
16:35–16:55
T-cell therapy in sarcoma: A hopeful future or unreachable reality?
Beyond traditional therapy: The impact of emerging approaches on sarcoma treatment
Sarcoma, CNS, head & neck and rare cancers
Satellite
Fri Oct 23
19:00–19:25
The implementation: Translating new evidence into effective clinical practice
F. Hoffmann - La Roche LTD - From evidence to action in HR+ HER2- mBC
Breast cancer
Chair
Sat Oct 24
08:30–10:00
Rapid oral: Investigational immunotherapy
with National Cancer Centre Singapore, University of Fribourg
Talk
Sat Oct 24
09:00–09:15
Beyond immune-checkpoint inhibition
Closing the gap: Promising therapeutic modalities in colorectal cancer
Gastrointestinal cancers
Talk
Sat Oct 24
09:30–09:50
Survival tactics: Adaptation mechanisms in metastatic tumors
Metastases: Understanding and targeting cancer spread
Biomarkers & precision oncology
Abstract
Sat Oct 24
09:32–09:44
Invited Discussant 1953RO and 1954RO
Rapid oral: Investigational immunotherapy
Keynote
Sat Oct 24
12:20–12:45
Chair
Sat Oct 24
14:45–16:15
Proffered paper: Gynaecological cancers
with Clínica Universidad de Navarra
Gynaecological cancers
Chair
Sat Oct 24
14:45–16:15
Rapid oral: Gastrointestinal tumours, lower digestive
with University College London Hospitals, Università Cattolica del Sacro Cuore
Gastrointestinal cancers
Abstract
Sat Oct 24
14:55–15:05
Abstract
Sat Oct 24
15:00–15:15
Invited Discussant 787RO, 788RO and 789RO
Rapid oral: Gastrointestinal tumours, lower digestive
Gastrointestinal cancers
Abstract
Sat Oct 24
15:15–15:27
Invited Discussant 1239O, LBA36 and LBA37
Proffered paper: Gynaecological cancers
Gynaecological cancers
Talk
Sun Oct 25
09:10–09:30
Refining endocrine therapy with CDK4/6 inhibitors in early breast cancer
Personalising treatment for patients with early stage HR+ breast cancer
Breast cancer
Chair
Sun Oct 25
10:15–11:45
Talk
Sun Oct 25
10:15–10:30
Multimodal automated integration of real-world data for outcome prediction
AI in cancer care: Transforming treatment, navigating challenges
Chair
Sun Oct 25
10:15–11:45
Talk
Sun Oct 25
10:15–10:30
The role of the oncologist in personalised prevention and early cancer detection
ESMO-ASCO: The evolving definition of the modern oncologist
Abstract
Sun Oct 25
11:00–11:10
Poster
Sun Oct 25
12:00–12:45
AI-driven drug discovery for gastroesophageal adenocarcinoma
Sunday Poster Display session 1
Gastrointestinal cancers
Poster
Sun Oct 25
12:00–12:45
Poster
Sun Oct 25
12:00–12:45
Pathogenic ATM loss defines pancreatic cancer (PC) with better prognosis, reduced liver tropism and distinct KRAS-tumor microenvironment (TME) biology
Sunday Poster Display session 4
Gastrointestinal cancersBiomarkers & precision oncology
Chair
Sun Oct 25
12:00–12:50
What oncologists should know about non-pharmaceutical interventions
with Canadian Cancer Trials Group, Oslo University Hospital
Nursing & supportive care
Talk
Sun Oct 25
12:30–12:45
Integrative oncology: What is the evidence?
What oncologists should know about non-pharmaceutical interventions
Nursing & supportive care
Chair
Sun Oct 25
14:45–16:00
LARC: The essential role of multidisciplinary management of locally advanced rectal cancer
with Vall d'Hebron University Hospital
Gastrointestinal cancers
Talk
Sun Oct 25
14:45–15:05
Locally advanced gastric and gastroesophageal cancer: Perioperative therapy
State-of-the-art treatment for non metastatic upper GI cancers
Gastrointestinal cancers
Chair
Sun Oct 25
14:45–16:25
Chair
Sun Oct 25
14:45–16:15
State-of-the-art treatment for non metastatic upper GI cancers
with Fondazione IRCCS Istituto Nazionale dei Tumori
Gastrointestinal cancers
Talk
Sun Oct 25
15:30–15:50
Tailoring post TNT strategies based on tumour response
LARC: The essential role of multidisciplinary management of locally advanced rectal cancer
Gastrointestinal cancers
Abstract
Sun Oct 25
15:35–15:45
Invited Discussant 3438O and 3439O
Proffered paper: Prevention, early detection and intervention
Chair
Sun Oct 25
16:30–17:15
Abstract
Sun Oct 25
17:54–18:06
Invited Discussant LBA8
Presidential Symposium II
Lung & thoracic cancersGastrointestinal cancers
Chair
Mon Oct 26
08:30–10:00
Rapid oral: Sarcoma
with Istituto Ortopedico Rizzoli, Vall d'Hebron Institute of Oncology (VHIO)
Sarcoma, CNS, head & neck and rare cancers
Abstract
Mon Oct 26
09:34–09:39
Abstract
Mon Oct 26
09:39–09:51
Invited Discussant 3723RO, 3724RO and 3725RO
Rapid oral: Sarcoma
Sarcoma, CNS, head & neck and rare cancers
Chair
Mon Oct 26
10:15–11:45
Rapid oral 2: Breast cancer, advanced stage
with Hospital Arnau de Vilanova, Peter MacCallum Cancer Centre
Breast cancer
Talk
Mon Oct 26
11:15–11:35
Immunotherapy in pancreatic cancer: Overcoming barriers to Success
Pancreatic cancer: From biology to emerging therapies
Gastrointestinal cancers
Abstract
Mon Oct 26
11:32–11:42
Invited Discussant 1769RO, 1770RO and 4449RO
Rapid oral 2: Breast cancer, advanced stage
Breast cancer
Poster
Mon Oct 26
12:00–12:45
A phase 2 study of ivonescimab (PD1/VEGF bispecific antibody) for the treatment of endometrial cancer (EC)
Monday Poster Display session 1
Gynaecological cancers
Poster
Mon Oct 26
12:00–12:45
A pooled analysis of zongertinib treatment in HER2-overexpressed/amplified NSCLC
Monday Poster Display session 5
Lung & thoracic cancers
Poster
Mon Oct 26
12:00–12:45
Poster
Mon Oct 26
12:00–12:45
Clinical outcomes and recurrence patterns in early-stage fusion-positive NSCLC treated with initial surgery or SBRT: A retrospective institutional analysis
Monday Poster Display session 3
Lung & thoracic cancersSarcoma, CNS, head & neck and rare cancers
Poster
Mon Oct 26
12:00–12:45
Endometrial cancer (EC): Patients (Pts) raise their voices
Monday Poster Display session 1
Gynaecological cancersNursing & supportive care
Poster
Mon Oct 26
12:00–12:45
Poster
Mon Oct 26
12:00–12:45
Molecular profiling of primary tumors and distant metastases in malignant mesotheliomas
Monday Poster Display session 4
Lung & thoracic cancersBiomarkers & precision oncology
Poster
Mon Oct 26
12:00–12:45
Neoadjuvant cemiplimab and cetuximab in resectable oral cavity squamous cell carcinoma (OCSCC)
Monday Poster Display session 2
Sarcoma, CNS, head & neck and rare cancers
Poster
Mon Oct 26
12:00–12:45
Talk
Mon Oct 26
12:00–12:15
Somatic vs germline: Avoiding the most common mistakes
What oncologists should know about interpreting tumour sequencing
Biomarkers & precision oncology
Chair
Mon Oct 26
12:00–12:50
What oncologists should know about interpreting tumour sequencing
with LMU University Hospital Munich, The Royal Marsden
Biomarkers & precision oncology
Abstract
Mon Oct 26
14:45–14:55
3808O - Tarlatamab in previously treated SCLC: Extended follow-up of overall survival from the phase 3 DeLLphi-304 trial
Proffered paper: Non-metastatic NSCLC and other thoracic malignancies
Lung & thoracic cancers
Talk
Mon Oct 26
14:50–15:10
Diagnostic and prognostic assessment
Modern management of leptomeningeal metastases
Sarcoma, CNS, head & neck and rare cancers
Talk
Mon Oct 26
15:10–15:35
Clinical trials and regulatory landscape in tumour-agnostic oncology
Tumour-agnostic oncology: From concept to clinical practice
Biomarkers & precision oncology

Explore the full ESMO 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Madrid. Leave your work email and we’ll be in touch.

Privacy

Download the full ESMO 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at Memorial Sloan Kettering Cancer Center

Tell us what you sell and we’ll find the people at Memorial Sloan Kettering Cancer Center most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction